According to Twist Bioscience 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -12.5676. At the end of 2022 the company had a P/E ratio of -6.17.
Year | P/E ratio | Change |
---|---|---|
2022 | -6.17 | -73.3% |
2021 | -23.1 | -54.55% |
2020 | -50.8 | 989.08% |
2019 | -4.67 | -23.99% |
2018 | -6.14 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Organovo ONVO | -0.5049 | -95.98% | ๐บ๐ธ USA |
Orchard Therapeutics
ORTX | -2.69 | -78.57% | ๐ฌ๐ง UK |
Novavax NVAX | -2.00 | -84.06% | ๐บ๐ธ USA |
Novocure
NVCR | -11.9 | -5.16% | Jersey |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.